All News
The AURORA 1 trial provided positive results for #lupus nephritis 👉rapid control of proteinuria w/o major side effects.
@RheumNow #ACR21 #YearinReview https://t.co/BWWZJtMPK0
sheila RHEUMarampa ( View Tweet)
To cut back or continue? 🤔
The ARCTIC REWIND trial showed that RA pts in remission given half dose csDMARDs had ⬆ flares in 12 mos vs. stable dose csDMARD grp.
@RheumNow #ACR21 #YearinReview https://t.co/MXyD0epVcn
sheila RHEUMarampa ( View Tweet)
Excited for the first full day of #ACR21, reporting for @RheumNow!
Esp looking forward to:
⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes
⭐Plenary session
⭐Scientific sessions covering #axSpA, #PsA and more
Mrinalini Dey DrMiniDey ( View Tweet)
Some great #SpA posters on #WorkParticipation
#ACR21
Abs#0358
•~700 pts
•379 (64.2%) took sick leave in last 12m
•#Absenteeism in 23.7% & #presenteeism in 84.1%
•Huge impact on work participation in SpA despite incr no. of therapeutic agents
@RheumNow
https://t.co/pwz4s8D1FU https://t.co/wpbjeXNpgm
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 1st/2 abstracts by @ElenaNikiUK on #work & #sickleave in #SpA
Abs#0380
•~700pts
•Old age & high disease activity👉🏼 ⬆️risk of sick leave
•Must address #socioeconomic factors w/ disease activity to improve work outcomes in #SpA
@RheumNow #ACRBest
https://t.co/uixuGGEFJG https://t.co/WZoqWLaY1Q
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 2nd abstract #0381 from #DESIR cohort by @ElenaNikiUK:
•High disease activity & decreased function assoc w/ greater #WorkDisability
•Not enough to just treat the disease! Need holistic approaches to improve function, QoL & work outcomes.
@RheumNow
https://t.co/jIs3Oj7nbJ
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs:
•High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m
•#Vaccination higher in ≥65yos than 50–64yos
•Need better vaccine policy to encourage uptake in pts w/ IMIDs
@RheumNow https://t.co/i5JDJClTyQ
Mrinalini Dey DrMiniDey ( View Tweet)
Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21
•No incr. risk of AEs in autoimmune disease vs controls
•Minimal impact of vaccines on disease activity
@RheumNow
https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX
Mrinalini Dey DrMiniDey ( View Tweet)
Well done 👏@DrCMcMaster @victor_yang1 on this great work - using machine learning to pick apart GCA from its mimics.
Predicting mimics improves prediction, especially in the quagmire of biopsy-negative GCA
(also excellent memes in this Twitter thread)
#ACR21 ABST1417 @RheumNow https://t.co/cS3fMLwem4
David Liew drdavidliew ( View Tweet)
@RheumNow Janet Zeide @Wharton - if the purpose = persuade:
e.g. persuading an audience, persuading pts to change
- ethos/logos/pathos
- remove barriers to action (cost of not changing, incremental change)
- state & refute counter-arguments
- know & engage your audience
#ACR21 @RheumNow https://t.co/JU2WeNYDvz
David Liew drdavidliew ( View Tweet)
So how do we treat this long COVID thing?
Some sensible hints here, but sadly I can't really say that we've got this under control. I feel helpless with the long COVID patients I've cared for.
#ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/Vaw0QlUx50
David Liew drdavidliew ( View Tweet)
Given the choice, you want me to risk long COVID?
No thanks. #GetVaccinated
#ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/TCao34vWK8
David Liew drdavidliew ( View Tweet)
This is priceless:
“Learning from our patients is a key highlight of #ACR21.” — Dr. S. Bhana
I could not agree more: a patient’s insight is invaluable, irreplaceable, and essential.
@RheumNow https://t.co/kS0NWVIpiG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️AMBITION trial data suggested combination of these meds might be more effective than either alone in patients with pulmonary arterial HTN.
➡️Ambrisentan + tadalafil
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️This type of vasculitis is most likely to cause proptosis
➡️GPA
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️This protean tumefactive disease can rarely present with orbital myositis.
➡️IgG4-related Disease
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️This is the most common chest imaging finding in a patient with relapsing chondritis
➡️ Tracheal Stenosis
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr. K Costenbader #ACR21 #YearinReview will cover important studies for #ClinicalPractice:
👉add on Therapies
👉 the JAK evolution
👉improving clinical care
👉disparities in care
@RheumNow https://t.co/dp1oeYMh8n
TheDaoIndex KDAO2011 ( View Tweet)
👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21
Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
TheDaoIndex KDAO2011 ( View Tweet)
Dr. K Costenbader #ACR21 #YearinReview add-ons Rx:
👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ
TheDaoIndex KDAO2011 ( View Tweet)